SubsidieMeestersRevolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
Diamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies.
Projectdetails
Introduction
At Diamante Società Benefit srl, we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP).
Technology Overview
Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotherapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease.
Proof-of-Concept Studies
Our proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects.
Treatment Benefits
Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune system’s ability to defend itself; hence reducing potential harmful side effects.
Funding Request
We are now seeking funding to cover the next clinical development steps.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- DIAMANTE SOCIETA BENEFIT S.R.Lpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargoThe project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods. | ERC POC | € 150.000 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC POC | € 150.000 | 2023 | Details |
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapyThe project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies. | ERC ADG | € 2.499.674 | 2024 | Details |
Driving tumour antigen presentation by RNA-mediated transdifferentiationDART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution. | ERC POC | € 150.000 | 2024 | Details |
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargo
The project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy
The project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies.
Driving tumour antigen presentation by RNA-mediated transdifferentiation
DART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution.